Sanofi is an international pharmaceutical company, which engages in the research and development, manufacturing and marketing of pharmaceutical drugs. It is also involved in research projects. PAREXEL is a consulting firm which conducts research for clients.
They are combining their clinical, regulatory, logistical and technical expertise in this trial, as well as their global presence. The objective is to demonstrate the relevance of data collected remotely and the overall feasibility of utilizing wearables in clinical trials.
Collecting data through wearables
It’s a way of conducting research that’s worth exploring more. It remains the question, however, how accurate these devices are and whether they can optimize study performance. The Sanofi-PARAXEL collaboration should offer more insight into these questions. In particular, the companies are examining how data collected from several wearable devices can be streamlined into a single, scalable data system to provide valuable insights.
Building on previous studies
It will be interesting to see whether this study comes to the same conclusion regarding the accuracy of wearables as the Stanford University study. While it’s certainly a very interesting subject, which needs to be explored in this day and age, one shouldn’t forget that both Sanofi and PAREXEL do benefit from a positive result.
Wearables are a core component of Sanofi’s digital trials strategy, as stated by Lionel Bascles, Global Head of Clinical Sciences and Operations of Sanofi. And PAREXEL’s Patient Sensor Solution focusses on data collected through wearables and other devices.